This is the authors' abstract. We don't add key points for this paper.
Lutein, a lipid soluble, oxygenated carotenoid, has shown beneficial effects against the risk factors associated with age-related macular degeneration, cardiovascular disease and also damaging UV radiation. The goal of the present study was to formulate lutein into a stable hydrophilic nanoemulsion that is more bioavailable and consumable in a matrix such as a beverage rather than just supplements. A Microfluidizer® Processor was used to convert an oil-in-water lutein emulsion into a nanoemulsion that is a stable water dispersion and measures 150 nm. After a one wk baseline phase, subjects consumed a lutein supplement pill followed by a lutein nanoemulsion added to orange juice (6 mg/d and 2 mg/d in two separate studies) for one wk each with a 2 wk washout phase between treatments. In study 1, mean serum lutein concentrations (n = 9) increased by 104% (P < 0.001) and 167% (P < 0.001) after the 6 mg supplement and nanoemulsion phases, respectively. In study 2, mean serum lutein concentrations (n = 11) increased by 37% (P < 0.05) and 75% (P < 0.001) after the 2 mg lutein supplement and nanoemulsion phases, respectively Despite the fact that the actual concentration of lutein in the 6 mg and 2 mg nanoemulsions was 10% and 40% lower compared to the supplement form, respectively, due to Microfluidizer ® processor preparation loss, the nanoemulsions resulted in 31% (P < 0.05) and 28% (P < 0.05) greater serum lutein concentrations compared to the supplement.. In conclusion, nanoemulsions of lutein had significantly greater bioavailability than the supplement-pill forms.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Vishwanathan et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: